Close Menu

microfluidics

The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated. 

The companies are joining BioView's Duet imaging system with Ruby Nanomed's Rubychip microfluidic device for circulating tumor cell isolation.

The Stanford University spinout cofounded by Euan Ashley will use the funding to develop its microfluidics-based cell sorting and analysis technology.

The researchers created a test-on-a-chip technology that takes about 35 minutes to produce a result, and may partner with Ford to produce the chips.

Developed by researchers at Yale University, the method, called deterministic barcoding in tissue sequencing, can map thousands of genes at 10 micron resolution.

The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.

Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago, and well above analysts' consensus estimate of $32.5 million.

The company's Advanta Dx SARS-CoV-2 RT-PCR assay received Emergency Use Authorization from the US Food and Drug Administration in August.

Funding for Fluidigm's assay through NIH's RADx program was increased by approximately $22 million for a total contract value of up to about $34 million.

The firm will use the funds to build inventory to meet anticipated demand, expand its sales and marketing efforts, and for general corporate purposes.

Pages

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.